Total Payments
$97,188
2024 Payments
$79,831
Companies
15
Transactions
114
Medicare Patients
11,714
Medicare Billing
$14.7M
Payment Breakdown by Category
Research$64,619 (66.5%)
Other$15,284 (15.7%)
Consulting$12,260 (12.6%)
Food & Beverage$3,730 (3.8%)
Travel$1,295 (1.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $64,619 | 25 | 66.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $14,617 | 5 | 15.0% |
| Consulting Fee | $12,260 | 5 | 12.6% |
| Food and Beverage | $3,730 | 68 | 3.8% |
| Travel and Lodging | $1,295 | 5 | 1.3% |
| Current or prospective ownership or investment interest | $666.71 | 6 | 0.7% |
Payments by Type
Research
$64,619
17 transactions
General
$32,569
89 transactions
Ownership
$0
8 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech, Inc. | $60,202 | 15 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $15,861 | 28 | $0 (2024) |
| Genentech USA, Inc. | $11,937 | 21 | $0 (2024) |
| F. Hoffmann-La Roche AG | $4,616 | 5 | $0 (2024) |
| ABBVIE INC. | $1,636 | 6 | $0 (2024) |
| Allergan, Inc. | $870.51 | 3 | $0 (2020) |
| US Retina LLC | $666.71 | 14 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $369.04 | 5 | $0 (2019) |
| Alcon Vision LLC | $335.55 | 6 | $0 (2024) |
| Astellas Pharma US Inc | $256.72 | 4 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $79,831 | 46 | Genentech, Inc. ($52,462) |
| 2023 | $11,784 | 13 | Genentech, Inc. ($7,550) |
| 2022 | $439.88 | 8 | US Retina LLC ($243.13) |
| 2021 | $389.89 | 5 | US Retina LLC ($235.99) |
| 2020 | $2,342 | 5 | Genentech USA, Inc. ($1,512) |
| 2019 | $562.80 | 11 | Regeneron Healthcare Solutions, Inc. ($173.18) |
| 2018 | $957.27 | 16 | Regeneron Healthcare Solutions, Inc. ($293.94) |
| 2017 | $880.09 | 10 | Genentech USA, Inc. ($608.06) |
All Payment Transactions
114 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $33.34 | General |
| Category: Ophthalmology | ||||||
| 12/12/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,640.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/06/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $62.50 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/21/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,640.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/15/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/19/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $32.15 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/18/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $151.92 | General |
| Category: Ophthalmology | ||||||
| 10/09/2024 | Genentech, Inc. | Lucentis (Biological) | — | Cash or cash equivalent | $2,195.00 | Research |
| Study: Port Delivery System of Ranibizumab Extension Study • Category: Ophthalmology | ||||||
| 10/08/2024 | Genentech, Inc. | Lucentis (Biological), Vabysmo | — | Cash or cash equivalent | $1,803.00 | Research |
| Study: MAD to assess the safety tolerability and PK PD in nAMD patients • Category: Ophthalmology | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | Lucentis (Biological) | — | In-kind items and services | $480.00 | Research |
| Study: Clinical Impact of the Port Delivery System With Ranibizumab (PDS) in Retinal Diseases • Category: Ophthalmology | ||||||
| 09/26/2024 | Genentech, Inc. | — | — | Cash or cash equivalent | $8,085.00 | Research |
| Study: A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA | ||||||
| 08/28/2024 | Genentech, Inc. | Lucentis (Biological), Susvimo, Vabysmo | — | Cash or cash equivalent | $16,539.00 | Research |
| Study: MAD to assess the safety tolerability and PK PD in nAMD patients • Category: Ophthalmology | ||||||
| 08/22/2024 | Alcon Vision LLC | Constellation (Device) | Food and Beverage | In-kind items and services | $94.30 | General |
| Category: Ophthalmology | ||||||
| 08/22/2024 | Alcon Vision LLC | Constellation (Device) | Food and Beverage | In-kind items and services | $27.39 | General |
| Category: Ophthalmology | ||||||
| 08/08/2024 | Genentech, Inc. | Lucentis (Biological), Susvimo | — | Cash or cash equivalent | $18,468.75 | Research |
| Study: Port Delivery System of Ranibizumab Extension Study • Category: Ophthalmology | ||||||
| 08/06/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $32.32 | General |
| Category: Ophthalmology | ||||||
| 07/22/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,081.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 07/18/2024 | Alcon Vision LLC | ARGOS (Device) | Food and Beverage | In-kind items and services | $30.93 | General |
| Category: Ophthalmology | ||||||
| 07/05/2024 | Genentech, Inc. | Lucentis (Biological), Susvimo | — | Cash or cash equivalent | $1,691.00 | Research |
| Study: Port Delivery System of Ranibizumab Extension Study • Category: Ophthalmology | ||||||
| 06/30/2024 | F. Hoffmann-La Roche AG | Lucentis (Biological) | — | In-kind items and services | $1,566.67 | Research |
| Study: STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA • Category: Ophthalmology | ||||||
| 06/30/2024 | F. Hoffmann-La Roche AG | Lucentis (Biological) | — | In-kind items and services | $919.11 | Research |
| Study: STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA • Category: Ophthalmology | ||||||
| 06/20/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $6.50 | General |
| Category: EYE CARE | ||||||
| 06/05/2024 | Alcon Vision LLC | Constellation (Device) | Food and Beverage | In-kind items and services | $136.19 | General |
| Category: Ophthalmology | ||||||
| 06/05/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $27.29 | General |
| 06/05/2024 | ABBVIE INC. | LUMIGAN (Drug) | Food and Beverage | In-kind items and services | $13.50 | General |
| Category: EYE CARE | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Port Delivery System of Ranibizumab Extension Study | Genentech, Inc. | $33,576 | 9 |
| MAD to assess the safety tolerability and PK PD in nAMD patients | Genentech, Inc. | $18,342 | 2 |
| A PHASE III STUDY TO INVESTIGATE RO7200220 IN PATIENTS WITH UVEITIC MACULAR EDEMA | Genentech, Inc. | $8,085 | 1 |
| STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | F. Hoffmann-La Roche AG | $4,136 | 4 |
| Clinical Impact of the Port Delivery System With Ranibizumab (PDS) in Retinal Diseases | F. Hoffmann-La Roche AG | $480.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 22 | 2,644 | 53,807 | $8.1M | $3.7M |
| 2022 | 23 | 3,018 | 18,052 | $8.4M | $3.7M |
| 2021 | 23 | 3,033 | 12,892 | $8.2M | $3.7M |
| 2020 | 24 | 3,019 | 12,718 | $8.0M | $3.6M |
Total Patients
11,714
Total Services
97,469
Medicare Billing
$14.7M
Procedure Codes
92
All Medicare Procedures & Services
92 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 213 | 2,434 | $3.7M | $1.7M | 45.6% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2023 | 119 | 43,920 | $2.2M | $1.3M | 58.0% |
| 67028 | Injection of drug into eye | Office | 2023 | 348 | 2,017 | $854,556 | $188,417 | 22.0% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2023 | 35 | 929 | $483,080 | $167,666 | 34.7% |
| J3490 | Unclassified drugs | Office | 2023 | 23 | 50 | $152,700 | $91,585 | 60.0% |
| 92134 | Imaging of retina | Office | 2023 | 732 | 2,683 | $246,495 | $79,170 | 32.1% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 414 | 469 | $89,402 | $42,060 | 47.0% |
| J2781 | Injection, pegcetacoplan, intravitreal, 1 mg | Office | 2023 | 11 | 300 | $60,000 | $36,108 | 60.2% |
| 67042 | Removal of membrane of retina with removal of internal limiting membrane of retina | Facility | 2023 | 28 | 29 | $83,346 | $26,356 | 31.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 195 | 278 | $37,616 | $18,505 | 49.2% |
| 67108 | Repair of detached retina with drainage and removal of eye fluid between lens and retina | Facility | 2023 | 19 | 19 | $58,026 | $17,934 | 30.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 144 | 158 | $31,284 | $15,366 | 49.1% |
| 67036 | Removal of eye fluid (vitreous) between lens and retina | Facility | 2023 | 15 | 17 | $31,059 | $11,883 | 38.3% |
| J7999 | Compounded drug, not otherwise classified | Office | 2023 | 28 | 141 | $19,035 | $10,093 | 53.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 56 | 56 | $17,024 | $6,221 | 36.5% |
| 92242 | Exam of retinal blood vessels and blood vessels between the white part of eye and retina using a special camera after injection of a dye | Office | 2023 | 25 | 32 | $9,234 | $4,954 | 53.7% |
| 92004 | New patient complete exam of visual system | Office | 2023 | 47 | 47 | $10,718 | $4,287 | 40.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 25 | 25 | $9,425 | $4,085 | 43.3% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 35 | 47 | $7,991 | $3,895 | 48.7% |
| 92250 | Photography of the retina | Office | 2023 | 89 | 105 | $12,786 | $2,636 | 20.6% |
| 92012 | Established patient problem focused exam of visual system | Office | 2023 | 28 | 31 | $4,140 | $1,842 | 44.5% |
| 76512 | 2d ultrasound scan of eye tissue and structures | Office | 2023 | 15 | 20 | $3,520 | $689.13 | 19.6% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 274 | 3,350 | $5.0M | $2.4M | 47.8% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2022 | 75 | 1,926 | $1.0M | $429,692 | 42.9% |
| 67028 | Injection of drug into eye | Office | 2022 | 397 | 2,163 | $929,604 | $202,833 | 21.8% |
About Dr. Robert Wirthlin, M.D
Dr. Robert Wirthlin, M.D is a Ophthalmology healthcare provider based in Spokane, Washington. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/25/2006. The National Provider Identifier (NPI) number assigned to this provider is 1013973254.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Wirthlin, M.D has received a total of $97,188 in payments from pharmaceutical and medical device companies, with $79,831 received in 2024. These payments were reported across 114 transactions from 15 companies. The most common payment nature is "" ($64,619).
As a Medicare-enrolled provider, Wirthlin has provided services to 11,714 Medicare beneficiaries, totaling 97,469 services with total Medicare billing of $14.7M. Data is available for 4 years (2020–2023), covering 92 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Location Spokane, WA
- Active Since 04/25/2006
- Last Updated 08/01/2024
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1013973254
Products in Payments
- Lucentis (Biological) $58,824
- EYLEA HD (Biological) $14,993
- Susvimo (Drug) $9,510
- EYLEA AFLIBERCEPT INJECTION (Biological) $643.80
- EYLEA (Biological) $592.70
- Constellation (Device) $257.88
- Izervay (Drug) $256.72
- Non-Covered Product (Drug) $189.72
- Vabysmo (Drug) $146.02
- OZURDEX (Drug) $128.73
- YUTIQ (Drug) $55.09
- BEOVU (Drug) $48.30
- Clareon (Device) $46.74
- ARGOS (Device) $30.93
- BYOOVIZ (Biological) $22.44
- LUMIGAN (Drug) $13.50
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Spokane
Dr. Barbara Smit, M.d, M.D
Ophthalmology — Payments: $157,604
Ophthalmology $157,604
Jessica Weinstein, M.d, M.D
Ophthalmology — Payments: $10,020
Ophthalmology $10,020
Dr. Gary Fillmore, M.d, M.D
Ophthalmology — Payments: $6,469
Ophthalmology $6,469
Shelly Lee, Md, MD
Ophthalmology — Payments: $3,546
Ophthalmology $3,546
Dr. Steven Day, M.d, M.D
Ophthalmology — Payments: $2,955
Ophthalmology $2,955
Heidi Eiseman, M.d, M.D
Ophthalmology — Payments: $2,197
Ophthalmology $2,197